MIDATECH PHARMA
MIDATECH PHARMA
Media
Media
Press Releases
LATEST
2017
2016
2015
ARCHIVE
Sep 28, 2018
Shareholder Circular and Notice of General Meeting to be held on 15 October 2018
Sep 28, 2018
Interim results from MTD201 exploratory study
Jun 8, 2018
Midatech Pharma US enrols first patient in Gelclair® trial in stem cell transplant
Jun 1, 2018
Board Change
Jun 1, 2018
2017 Annual Report and AGM Notification
May 25, 2018
Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer
Mar 21, 2018
Midatech commences dosing in equivalence study
Mar 15, 2018
Midatech announces changes in Senior Management Team
Jan 9, 2018
Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved
Jan 2, 2018
Midatech enters into a Loan Agreement with MidCap Financial
Dec 20, 2017
Midatech Pharma US initiates Gelclair® Phase IV trial to study oral mucositis in stem cell transplant patients
Sep 6, 2017
Midatech to present at 19th Annual Rodman & Renshaw Global Investment Conference
Sep 4, 2017
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly
Jul 26, 2017
Completion of pre-clinical liver cancer programme
Jul 18, 2017
Trading Update and Notice of Results
May 22, 2017
Midatech announces progress update on brain cancer therapies
Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016
Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
Jan 10, 2017
Trading Update and Notice of Results
Nov 22, 2016
Midatech provides update on agreement with Emergex Vaccines
Nov 15, 2016
Midatech selects MTR104 candidate for treatment of liver cancer
Sep 30, 2016
Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle Technology
Sep 21, 2016
Midatech Pharma US Announces Partnership with R-Pharm US to Co-promote Zuplenz® (ondansetron) oral soluble film and Oravig® (miconazole) orally-dissolving buccal tablet
Sep 2, 2016
Interim results for the six months ended 30 June 2016